Form 4: Alnylam CEO Yvonne Greenstreet Reports Stock Sale Under 10b5-1 Plan

Alnylam Pharmaceuticals CEO Yvonne Greenstreet sold 7,093 shares of common stock on July 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 11, 2024, Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, sold 7,093 shares of common stock at a price of $261 per share.
• The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on March 12, 2024.
• Following the transaction, Greenstreet directly owns 73,441 shares of Alnylam common stock.
• Additionally, Greenstreet indirectly owns 407 shares through a managed account related to the issuer's 401(k) plan.

Sentiment

Score: 5

Explanation: The document is a routine SEC Form 4 filing reporting a stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Sales by company insiders are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares over a period of time while avoiding concerns about insider trading. The market typically views these sales in the context of the overall financial health and prospects of the company.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates